Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Marqués de Valdecilla (28)

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2022

  1. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

2020

  1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116

2019

  1. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383

  2. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open, Vol. 4, Núm. 6

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

2015

  1. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

  2. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

  3. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

2014

  1. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 865-878

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  4. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

    Oncologist, Vol. 17, Núm. 3, pp. 339-345

  5. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: Relationship between skin rash and survival (Pantar study)

    Annals of Oncology, Vol. 23, Núm. 7, pp. 1919-1925

  6. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

2009

  1. Consensus on the treatment of pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 11, Núm. 5, pp. 290-301